BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 16927538)

  • 1. Effects of irsogladine on P450-isoform specific activities in human hepatic microsomes.
    Nakamura A; Tougou K; Kitazumi H; Yamada T; Honjou K; Nonaka K; Mukai H
    Arzneimittelforschung; 2006; 56(7):547-52. PubMed ID: 16927538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of etodolac on P450 isoform-specific activities in human hepatic microsomes.
    Nakamura A; Tougou K; Kitazumi H; Yamada T; Honjou K; Zinno A; Nonaka K; Mukai H
    Arzneimittelforschung; 2005; 55(12):744-8. PubMed ID: 16430028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
    Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
    Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
    Wen X; Wang JS; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.
    Sahi J; Black CB; Hamilton GA; Zheng X; Jolley S; Rose KA; Gilbert D; LeCluyse EL; Sinz MW
    Drug Metab Dispos; 2003 Apr; 31(4):439-46. PubMed ID: 12642470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes.
    Yamazaki H; Shimada T
    Xenobiotica; 1999 Mar; 29(3):231-41. PubMed ID: 10219964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
    Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
    Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isoform selective inhibition and inactivation of human cytochrome P450s by methylenedioxyphenyl compounds.
    Nakajima M; Suzuki M; Yamaji R; Takashina H; Shimada N; Yamazaki H; Yokoi T
    Xenobiotica; 1999 Dec; 29(12):1191-202. PubMed ID: 10647906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms.
    Renwick AB; Surry D; Price RJ; Lake BG; Evans DC
    Xenobiotica; 2000 Oct; 30(10):955-69. PubMed ID: 11315104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes.
    Ramírez J; Innocenti F; Schuetz EG; Flockhart DA; Relling MV; Santucci R; Ratain MJ
    Drug Metab Dispos; 2004 Sep; 32(9):930-6. PubMed ID: 15319333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin.
    Heyn H; White RB; Stevens JC
    Drug Metab Dispos; 1996 Sep; 24(9):948-54. PubMed ID: 8886603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes.
    Yao HT; Chang YW; Lan SJ; Chen CT; Hsu JT; Yeh TK
    Life Sci; 2006 Nov; 79(26):2432-40. PubMed ID: 16978661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype.
    Kiang TK; Ho PC; Anari MR; Tong V; Abbott FS; Chang TK
    Toxicol Sci; 2006 Dec; 94(2):261-71. PubMed ID: 16945988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA.
    Jacobson PA; Green K; Birnbaum A; Remmel RP
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):461-7. PubMed ID: 12107550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of cefixime and cefdinir, oral cephalosporins, on cytochrome P450 activities in human hepatic microsomes.
    Niwa T; Shiraga T; Hashimoto T; Kagayama A
    Biol Pharm Bull; 2004 Jan; 27(1):97-9. PubMed ID: 14709907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytochrome P450 metabolic dealkylation of nine N-nitrosodialkylamines by human liver microsomes.
    Bellec G; Dréano Y; Lozach P; Ménez JF; Berthou F
    Carcinogenesis; 1996 Sep; 17(9):2029-34. PubMed ID: 8824531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
    Ball SE; Ahern D; Scatina J; Kao J
    Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dehydrogenation of indoline by cytochrome P450 enzymes: a novel "aromatase" process.
    Sun H; Ehlhardt WJ; Kulanthaivel P; Lanza DL; Reilly CA; Yost GS
    J Pharmacol Exp Ther; 2007 Aug; 322(2):843-51. PubMed ID: 17502430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
    Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
    Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease.
    Fisher CD; Lickteig AJ; Augustine LM; Ranger-Moore J; Jackson JP; Ferguson SS; Cherrington NJ
    Drug Metab Dispos; 2009 Oct; 37(10):2087-94. PubMed ID: 19651758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.